金石亚药 reported revenue of ¥0.49B for the period ended 2026-06-30, -0.2% year on year. Net income was ¥0.09B, a 19.3% net margin on a 60.5% gross margin. The largest revenue line is 药品、保健品及食品销售收入 at 87% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.49B | -0.2% |
| Gross profit | ¥0.30B | — |
| Operating income | ¥0.11B | — |
| Net income | ¥0.09B | +47.2% |
| Gross margin | 60.5% | Net margin 19.3% |
| Revenue Q/Q | -52.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品、保健品及食品销售收入 | ¥0.43B | 87.0% |
| 生产线及配套销售收入 | ¥0.05B | 10.1% |
| 其他(补充) | ¥0.01B | 2.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.19B | 39.5% |
| R&D | ¥0.02B | 5.0% |
| SG&A | ¥0.16B | 31.7% |
| Tax & other | ¥0.02B | 3.7% |
| Item | Amount |
|---|---|
| Total assets | ¥3.13B |
| Total liabilities | ¥0.49B |
| Shareholders' equity | ¥2.64B |
| Equity / assets | 84.2% |
| Operating cash flow | ¥0.13B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 113% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中泰股份 ・ 广生堂 ・ 清水源 ・ 鹏辉能源 ・ 美康生物 ・ 运达科技 ・ 鲍斯股份 ・ 金雷股份 ・ 双杰电气 ・ 康斯特 ・ 航天智造 ・ 全信股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies